Coherus BioSciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Coherus BioSciences, Inc. on August 1, 2019. The filing serves to announce the company's financial results for the second quarter ended June 30, 2019. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Market under the symbol CHRS.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were issued in a press release, which is attached as Exhibit 99.1, but the text of the press release is not included in the input data.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only references the issuance of the Q2 2019 results.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risks, contingencies, or unusual items. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 1, 2019) for actual Q2 2019 financial figures.
- Verify the specific revenue and net loss numbers for the quarter ended June 30, 2019.
- Check for any updated full-year 2019 guidance provided in the press release.
- Confirm cash position and burn rate details not present in this summary text.